Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed, and dated informed consent as defined by the Institutional Review Board.~* Male and female patients older than 18 years of age undergoing primary elective hip, knee or shoulder arthroplasty.~* Documented nasal carriage of MRSA.~* If a female of childbearing potential the patient should agree to practice a reliable contraceptive method (e.g. birth control pills, condoms, or intrauterine device \[IUD\]) during treatment and for one month after receiving the study medication.~Exclusion Criteria:~* Concurrent urinary tract infection or colonization unless treated with evidence of microbiologic cure.~* Evidence of active infection elsewhere other than urinary tract, unless treated with evidence of microbiologic cure documented by the infectious diseases service.~* Patients undergoing elective secondary arthroplasty.~* Concurrent open wounds~* Pregnant and nursing women (if patient is still of childbearing potential, a negative serum pregnancy test will be confirmed).~* History of allergy or contraindication to study drugs.~* Weight \>150 kg or \<50kg~* Patients with creatinine clearance (CLcr) \< 30ml/min (calculated using the Cockcroft-Gault equation using ideal body weight)~* Severe neutropenia (absolute neutrophil count \<0.500x103 /µl).~* Patients considered unlikely to comply with study procedures or to return for the scheduled post treatment evaluation.~* Ongoing antibiotic therapy for active infection that is anticipated to continue until the day of surgery.~* Any other condition that in the opinion of the investigator, would confound or interfere with evaluation of safety or efficacy of the investigational medication, or prevent compliance with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin (Type: EXPERIMENTAL): Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
- Vancomycin (Type: ACTIVE_COMPARATOR): Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).